CRLCharles River Laboratories

Charles River is a full-service non-clinical drug development partner. It sells research models, discovery and safety assessment services, and manufacturing support for preclinical and early-development work; after the May 2026 divestitures of CDMO, Cell Solutions, and certain European Discovery Services sites, the public mix is more concentrated in the core preclinical franchise.

Charles River monetizes the regulated gate before a molecule enters human trials. Sponsors outsource because the preclinical workflow is long, expensive, and hard to re-qualify; CRL’s control point is validated model supply plus GLP/non-GLP study infrastructure plus sponsor workflow embedment.

• The Q2 2026 release said non-GAAP operating margin improved 420 bps sequentially to 20.5%, while GAAP operating margin held at 11.9%.
• DSA revenue was $606.5M, down 1.9% YoY, but organic revenue still improved 0.2% on higher regulated safety-assessment study volume.
• Manufacturing revenue was $188.1M, down 6.3% YoY because of the CDMO divestiture, but organic revenue grew 1.3% on higher Microbial Solutions revenue.
• Management increased 2026 guidance: organic revenue guidance rose by 150 bps and non-GAAP EPS midpoint rose by $0.25, citing improving DSA demand and better-than-expected Manufacturing performance.
• The company repurchased $100M of stock in Q2 and $300M year-to-date, leaving $700M authorized under the $1.0B buyback program.
• The 10-Q says CRL remains a leading non-clinical global drug-development partner with research models, GLP and non-GLP discovery/safety assessment, and manufacturing support across major pharma, biotech, medtech, diagnostics, and government clients.